To me it seems there's enough cash in hand for the present, and that any CR need not be required before mid-2013, which as interestedtoo suggests quite reasonably, could be made on the back of announcements on very good progress on the current trials. It would be helpful if VLA would undertake now that no CR will be entertained for issue before that mid-2013.
Nevertheless, I support Orange's questions about Resolution 5, and his/her other comments. I do not think a potential 25% dilution should be supported simply because it seems a good idea at the time. There has to be good reason; if there is, I'd like to know what it is.
I'd like to know why we now have only one IND trial underway, with only 13 patients, when a year ago at the last AGM it was stated that an intravenous trial would be pursued as a major priority. Why so slow on the patient takeup? And why no news on the application for an IV trial?
I'm also not happy about Resolution 4. I'm also voting against the Remuneration Report. And why aren't more researchers being given options? For goodness sake, it's their brains and commitment that are the key to this company!
At the AGM on Thursday of next week, I'll be very inerested to find out what the new CEO perceives as priorities for VLA, and for his own next few months.
As I've noted previously, I think the technology of virotherapy has great promise, and I believe CAVATAK may prove very effective. But it is easy enough to drop the ball. That's my concern.
VLA Price at posting:
38.2¢ Sentiment: LT Buy Disclosure: Held
